Presenteeism: At Work--But Out of It

Employers are beginning to realize that they face a nearly invisible but significant drain on productivity: presenteeism, the problem of workers being on the job but, because of illness or other medical conditions, not fully functioning. By some estimates, the phenomenon costs U.S. companies more than $150 billion a year--much more than absenteeism does. Yet, it's harder to identify. As companies struggle to rein in health care costs, most overlook what may be a $150 billion problem: the nearly invisible drain on worker productivity caused by such common ailments as hay fever, headaches, and even heartburn. However, a handful of companies are recognizing the problem of presenteeism and trying to do something about it.
Due to copyright issues, this study is only available through the Harvard Business Review website.
E.V.I.dently May 2013
Message From NPCThe Role of Pharmaceuticals in Health Insurance ExchangesOne of the most pressing issues in the implementation of the Affordable Care...The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer
WASHINGTON, DC (April 24, 2013) The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (...NPC Welcomes Dr. Bryan Luce as PCORI Chief Science Officer
WASHINGTON, DC (April 24, 2013) The National Pharmaceutical Council today welcomed the news that the Patient-Centered Outcomes Research Institute (...Study Quantifies Impact of Pharmaceuticals on Enhanced Productivity
(WASHINGTON, DC, August 1, 2012)–The costs to employers of chronic health conditions on employee productivity are well documented, but few studies...Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals
WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...New Survey Shows Employers Eyeing CER, PCORI for Health Information
Washington, DC, June 22, 2011--Employers are aware of comparative effectiveness research (CER) and its potential to answer critical questions about...Living Up to Its Name? The Role of Patient-Centered Research
Anyone who has ever received bad news from his or her health care provider or held a loved one’s hand when a diagnosis was delivered can understand...High Stakes for Setting Research Standards
What is the cost of poorly designed research? In the comparative effectiveness arena, faulty studies could mean that consumers may make important...Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
The number of voices in the comparative effectiveness research (CER) conversation is continuing to grow, but not all stakeholders have the same...Comparative Effectiveness Research and the Changing Health Care Landscape
This content appeared in the January 2, 2012 print edition of Chain Drug Review. In the span of just one year, the health care landscape has...Getting Patients Engaged in Comparative Effectiveness Research
Marc Boutin, EVP...Do Patients Understand Comparative Effectiveness Research?
Marc Boutin, EVP...PCORI Outlines Efforts to Engage Patients
Dr. Rachael Fleurence, Scientist,Patient-Centered Outcomes Research Institute, outlines the many ways heragency is engaging patients and other...Patient Usability Criteria for Comparative Effectiveness Research
Marc Boutin, EVP...The Role of Pharmaceuticals in Health Insurance Exchanges
As part of the implementation of the Affordable Care Act, a series of state health insurance exchanges are being established across the United States...A Look at Rx Coverage and Cost in the New Health Insurance Exchanges
National Pharmaceutical Chief Science Officer Dr. Robert Dubois will lead a panel discussion, "Capturing the Value of Pharmaceuticals--A Look at Rx...NPC's Dr. Dubois Talks ACO Expectations at AMCP Meeting
NPC's Chief Science Officer Dr. Robert Dubois chats with the American Journal of Managed Care about expectations for implementing accountable care...NPC to Present at IBI/NBCH 2013 Health and Productivity Forum
NPC Director of Policy Research Dr. Daryl Pritchard will speak on employer challenges in addressing specialty pharmacy-related impacts at the...Research
Intended and Unintended Consequences of HMO Cost Containment Strategies: Results from the Managed Care Outcomes Project
In examining the various cost-containment strategies
Availability of New Drugs and Americans' Ability to Work
This work examined the extent to which the introduct
- 1 of 32
- >
Commentary & Testimony
Living Up to Its Name? The Role of Patient-Centered Research
High Stakes for Setting Research Standards
Asymmetry in the Ability to Communicate CER Findings: Ethics and Issues for Informed Decision Making
Comparative Effectiveness Research and the Changing Health Care Landscape
CER Done Right: Why It Matters